{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:04:48Z","timestamp":1792695888554,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2637,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","award":["ZOL-MRD 001"],"award-info":[{"award-number":["ZOL-MRD 001"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1093\/annonc\/mdr612","type":"journal-article","created":{"date-parts":[[2012,3,3]],"date-time":"2012-03-03T23:16:46Z","timestamp":1330816606000},"page":"2271-2277","source":"Crossref","is-referenced-by-count":59,"title":["Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients"],"prefix":"10.1016","volume":"23","author":[{"given":"E.-F.","family":"Solomayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hirnle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Janni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-J.","family":"L\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Huober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Wackwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wallwiener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Fehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr612_bb0010","series-title":"Global Cancer Facts & Figures 2007","author":"Garcia","year":"2007"},{"key":"10.1093\/annonc\/mdr612_bb0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BD-2007-26106","article-title":"Priming the \u2018soil' for breast cancer metastasis: the pre-metastatic niche","volume":"26","author":"Psaila","year":"2006","journal-title":"Breast Dis"},{"key":"10.1093\/annonc\/mdr612_bb0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1006308619659","article-title":"Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis","volume":"59","author":"Solomayer","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdr612_bb0025","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdr612_bb0030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4065\/84.6.533","article-title":"Treatment options for breast cancer resistant to anthracycline and taxane","volume":"84","author":"Moreno-Aspitia","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1093\/annonc\/mdr612_bb0035","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2008.48","article-title":"The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites","volume":"22","author":"Shiozawa","year":"2008","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdr612_bb0040","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMoa050434","article-title":"A pooled analysis of bone marrow micrometastasis in breast cancer","volume":"353","author":"Braun","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr612_bb0045","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/1078-0432.CCR-07-4749","article-title":"Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse","volume":"14","author":"Bidard","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr612_bb0050","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/annonc\/mdp200","article-title":"Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer","volume":"20","author":"Bidard","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr612_bb0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10549-006-9484-5","article-title":"Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients","volume":"106","author":"Becker","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl","key":"10.1093\/annonc\/mdr612_bb0060","first-page":"74s","article-title":"The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving letrozole: 36 months follow-up of ZO-FAST","volume":"69","author":"Eidtmann","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdr612_bb0065","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr612_bb0070","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdr612_bb0075","first-page":"1807","article-title":"Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer","volume":"30","author":"Rack","year":"2010","journal-title":"Anticancer Res"},{"issue":"Suppl","key":"10.1093\/annonc\/mdr612_bb0080","first-page":"20s","article-title":"Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr612_bb0085","series-title":"Zometa\u00ae (zoledronic acid) Injection [Prescribing Information]","year":"2011"},{"key":"10.1093\/annonc\/mdr612_bb0090","unstructured":"US Food and Drug AdministrationCFR\u2014Code of Federal Regulations Title 21: Title 21\u2014Food and Drugs Chapter I\u2014Food and Drug Administration Department of Health and Human Services Subchapter A\u2014General Provisions: Part 50\u2014Protection of Human Subjectshttp:\/\/www.accessdata.fda.gov\/SCRIPTs\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm. (22 December 2010, date last accessed)"},{"key":"10.1093\/annonc\/mdr612_bb0095","doi-asserted-by":"crossref","unstructured":"Directive 2001\/83\/EC of The European Parliament and of The Council of 6 November 2001 on the Community Code relating to medicinal products for human use. Official Journal L\u2014311, 28\/11\/2004, pp. 67\u2013128. http:\/\/www.emea.europa.eu\/pdfs\/human\/pmf\/2001-83-EC.pdf. (22 December 2010, date last accessed)","DOI":"10.3233\/PPL-2009-0234"},{"key":"10.1093\/annonc\/mdr612_bb0100","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/cncr.22076","article-title":"A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation","volume":"107","author":"Fehm","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdr612_bb0105","first-page":"3552","article-title":"Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging","volume":"6","author":"Bauer","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdr612_bb0110","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1053\/j.seminoncol.2010.06.008","article-title":"Potential anticancer properties of bisphosphonates","volume":"37","author":"Neville-Webbe","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdr612_bb0115","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Coleman","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdr612_bb0120","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdr612_bb0125","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr612_bb0130","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/ijc.24470","article-title":"The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis","volume":"125","author":"Zarogoulidis","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdr612_bb0135","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/cyto.b.20114","article-title":"A European interlaboratory testing of three well-known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow","volume":"70B","author":"Borgen","year":"2006","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1093\/annonc\/mdr612_bb0140","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","article-title":"Exploring the anti-tumour activity of bisphosphonates in early breast cancer","volume":"34","author":"Winter","year":"2008","journal-title":"Cancer Treat Rev"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341935183X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341935183X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/9\/2271\/964839\/mdr612.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T09:27:14Z","timestamp":1624440434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341935183X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S092375341935183X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr612","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}